11/7/26 Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Previous One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Next Learning More from Less: Smarter Design and Execution in Rare Disease Trials You Might Also Like Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients. The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle
11/7/26 Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Previous One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Next Learning More from Less: Smarter Design and Execution in Rare Disease Trials You Might Also Like Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients. The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle
